Blueprint Medicines Corporation
BPMC
Hisse Senetlerindeki Sıralama
#2355
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Hisse Fiyatı
$129.46
Son senkronizasyon: 2025-07-18
Piyasa Değeri
$8.36B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Blueprint Medicines Corporation (BPMC)
Kategori
Healthcare
Blueprint Medicines Corporation (BPMC) için kazanç
Mar 2025 itibarıyla kazanç TTM: $-153.89M
Blueprint Medicines Corporation şirketinin en son finansal raporlarına göre, mevcut kazancı $-153.89M'dir. 2023 yılında şirket $-506.02M kazanç elde etti, bu 2022 yılındaki $-552.28M kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Blueprint Medicines Corporation için kazanç geçmişi 2013 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-153.89M | 133.66% |
| 2024 | $-65.86M | -86.98% |
| 2023 | $-506.02M | -8.38% |
| 2022 | $-552.28M | -13.85% |
| 2021 | $-641.08M | -303.56% |
| 2020 | $314.94M | -190.58% |
| 2019 | $-347.69M | 46.93% |
| 2018 | $-236.64M | 59.76% |
| 2017 | $-148.12M | 104.32% |
| 2016 | $-72.50M | 37.38% |
| 2015 | $-52.77M | 30.99% |
| 2014 | $-40.29M | 92.64% |
| 2013 | $-20.91M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -3,527.62% |
US
|
|
| $-3.09B | 1,905.93% |
US
|
|
| $-4.02B | 2,509.72% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,367.53% |
NL
|
